Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 155   

Articles published

MRK 59.66 0.00 (0.00%)
price chart
Medical Breakthroughs On The Horizon For Merck (MRK)
Merck (MRK) is a global health care company that includes prescription medicines; vaccines, biologic therapies, animal health and consumer care products.
Merck & Co., Inc. Tops Earnings, Misses Revenue Estimates
Merck & Co., Inc. (NYSE:MKR) released the earnings results from its third quarter this morning before opening bell, posting adjusted earnings of 90 cents per share on $10.56 billion in revenue.
Related articles »  
Anti-PD-1 Drug Keytruda Gives Merck & Co. (MRK) Reason To Rejoice Again
Merck & Co., Inc. (NYSE:MRK) has announced positive Phase II trial results for its anti-PD-1 therapy Keytruda (pembrolizumab).
Merck & Co., Inc. (NYSE:MRK) Reports Results from Hepatitis C Treatment
Merck & Co., Inc. (NYSE:MRK) reported Tuesday promising results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir, a product to treat the chronic hepatitis C virus genotype 1 in treatment-naive and previously-treated patients.
Merck Reports Interim Data on Hepatitis C Virus Drug  Yahoo News
Related articles »  
Interesting January 2017 Stock Options for Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
Merck & Co.'s (MRK) Cholesterol Drug Vytorin Reduced Risk Of Heart Attacks ...
Merck & Co., Inc.'s (NYSE:MRK) cholesterol drug Vytorin was successful in meeting the primary endpoint of lowering the risks of second heart attacks in patients already undergoing an aggressive treatment, results from a study of the drug show.
Merck Shares May Have Hit A Ceiling For The Most Recent Upside Move
Merck & Co., Inc. (NYSE: MRK) stock participated in the market's recent upside like most other U.S. equity issues. However, unlike some that broke out to new highs, Merck shares seem to have "hit the wall" in terms of upside momentum at just above $60.
Merck & Co. Shares Gap Down on Insider Selling (MRK)  Mideast Time
News Buzz � Merck & Co., Inc. (NYSE:MRK), Gilead Sciences, Inc. (NASDAQ ...  Techsonian (press release)
Related articles »  
Merck & Co., Inc. (MRK): Hal Mintz, Stan Druckenmiller Are Bullish on This ...
Merck & Co., Inc. (NYSE:MRK) is one of the stocks that has seen an increase in bullish sentiment among hedge funds, with Hal Mintz, Stan Druckenmiller and several other investors joining the list.
NewLink Genetics, Merck & Co. (MRK) In Talks To Scale Up Ebola Vaccine ...
NewLink Genetics Corp (NASDAQ:NLNK) and Merck & Co., Inc. (NYSE:MRK) are rumored to have come to the table for talks to research possible ways to increase the production of NewLink's experimental Ebola vaccine.
NewLink in Talks With Merck on Producing Ebola Vaccine  Bloomberg
Related articles »  
Stock Watch: Merck & Co., Inc. (NYSE:MRK)
[Zacks] Merck & Co., Inc. (NYSE:MRK) announced positive results from a pivotal phase II study (KEYNOTE-002) on its anti-PD-1 therapy, Keytruda (pembrolizumab).
Mix Sector Stock In Focus: Merck & Co. Inc. (NYSE:MRK), ShoreTel, Inc ...  Street Newswire (registration)
Related articles »